Healthbeat Report: Predicting Parkinson’s

by Sylvia Perez and Christine Tressel

May 24, 2012 (CHICAGO) -- Colonoscopies are known for detecting early signs of cancer in the colon. Now Chicago researchers say this common test may help reveal who might be at risk of developing Parkinson's disease. They have discovered a clue in the gut that could be a game changer for early diagnosis and even treating the disease.

Richard Fiske Bailey says even he had a hard time realizing something was happening with his body. It was the way he was driving his sports car that caught the attention of friends.

"When I went to shift gears I would reach down with my left hand and shift I would shift with my left hand instead of my right hand, I never noticed it. And people would start to say, what is wrong," Fiske said.

It took a long time but eventually he had a diagnosis: Parkinson's disease.

"I was formally diagnosed in 2003 by my fifth neurologist," Fiske said.

A slight tremor in a hand, tense muscles and slow movements are some of the more distinctive signs suggesting Parkinson's disease. But even these can be confused with other conditions. That means thousands of cases are not diagnosed until a lot of brain cells are gone.

Parkinson's disease occurs when the nerve cells in the brain that make a chemical called dopamine are slowly destroyed. No one is sure why that happens.

Now researchers are turning to what would seem an unlikely source of a brain disorder: the gut.

"This area of research is really hot right now, and we think it's really important," said Dr. Kathleen Shannon, neurologist, Rush University Medical Center

More:
Healthbeat Report: Predicting Parkinson's

Recovery From Multiple Sclerosis By Growth Factor In Stem Cells

Editor's Choice Main Category: Multiple Sclerosis Article Date: 24 May 2012 - 14:00 PDT

Current ratings for: 'Recovery From Multiple Sclerosis By Growth Factor In Stem Cells'

5 (2 votes)

4.5 (2 votes)

Animals that were injected with hepatocyte growth factor were noted to have grown new neural cells and lower levels of inflammation. Most significantly, the researchers noted that the protective envelope of myelin, the myelin sheath, which surrounds the core of a nerve fiber and facilitates the transmission of nerve impulses, re-grew and covered lesions that were caused by MS.

Robert H. Miller, professor of neurosciences at the School of Medicine and vice president for research at Case Western Reserve University declared: "The importance of this work is we think we've identified the driver of the recovery."

MS is caused by damage to the myelin sheath, the protective covering that surrounds nerve cells. The nerve damage is caused by inflammation, which occurs when the body's own immune cells attacks the nervous systems located in areas of the brain, the optic nerve, and spinal cord. This damage can cause an interruption of the nerve signals, which results in loss of balance and coordination, cognitive ability, as well as in other functions and in time, these intermittent losses may become permanent. In 2009, Caplan and Miller discovered that mice with MS injected with human mesenchymal stem cells recovered from the type of damage that was brought on by MS. A clinical trial is currently underway based on their research, whereby patients with MS are injected with their own stems cells.

During this trial, the team decided to first establish whether the presence of stem cells or other cells induce recovery. They injected a total of 11 animals with MS with the medium, in which mesenchymal stem cells that were taken from bone marrow grew, discovering that all animals displayed a rapid reduction in functional deficits. An analysis demonstrated that unless the injected molecules had a certain size or weight, i.e. between 50 and 100 kiloDaltons, the course of the disease remained unchanged.

Other research, as well as the team's own studies, suggested that this was likely to be instigated by the hepatocyte growth factor, which is secreted by mesenchymal stem cells.

The team then injected the animals with either 50 or 100 nanograms of the growth factor on alternate days for a 5-day period and observed a decrease in the level of signaling molecules that promote inflammation, whilst the level of signaling molecules that oppose inflammation increased. The researchers noted a growth of neural cells, whilst nerves that were exposed because of MS were rewrapped with myelin. Recovery was marginally better in those mice that received the 100-nanogram injections compared with those receiving the 50-nanogram injections.

Original post:
Recovery From Multiple Sclerosis By Growth Factor In Stem Cells

Multiple sclerosis walk-through

Participants warm up for the walk held in conjunction with World Multiple Sclerosis Day. Pix by Iqmal Haqim Rosman

Padma Panikker says many know little about the rare disease, a situation that the Multiple Sclerosis Society Malaysia hopes to change. Pix by Iqmal Haqim Rosman

IN conjunction with World Multiple Sclerosis Day on May 30, a charity walk was held at Titiwangsa Lake.

Organised by Multiple Sclerosis Society Malaysia and supported by Novartis Corporation (M) Sdn Bhd, the event had the support of 300, who walked around the lake wearing the society's official T-shirt.

The walk was flagged off by model Amber Chia, who was there to show support to the cause and learn more about the disease.

"I heard that the percentage of Malaysians with the disease is low, and some do not even know they have it.

"I am here to learn more about the disease. I hope that more people will be aware of multiple sclerosis after this," she said.

Chia said she did not know much about the disease before she was invited to the event, and was surprised by some of the things she had learnt.

"For example, I thought that only old people get it but some of the patients here have got the disease since they were 13," said Chia.

Multiple Sclerosis Society Malaysia president Padma Panikker said those who were diagnosed with the disease were usually frightened at first and the society acted as a support group for them.

See the original post:
Multiple sclerosis walk-through

NZACA Welcomes $7 million Increase for Dementia

NZACA Welcomes $7 million Increase for Dementia

NZACA Press Release 24 May 2012

NZACA welcomes the governments $7 million p.a. increase for dementia care announced today.

The budget announcement of $40 million for dementia is arrived at by adding together, over a four year period, yearly increases along with the additional funding required to cover demand growth.

This represents a 5.8% increase in the daily subsidy rate and taking into inflationary pressures of 1.8% this represents a 4% overall gain for dementia care operators.

The average amount paid for dementia care per day is $149 depending on where you live in New Zealand.

This is another good increase in the dementia rate and means the underfunding of this service has reduced from about 36% to 20% in the last two years based on the independent 2010 Aged Residential Care Review paid for by the Government, the Chief Executive of NZACA, Martin Taylor, said today.

Everyone in the aged-care sector and the health sector understands the demand for dementia care will increase dramatically and that it is one of the hardest services to deliver. As such this increase will be of great assistance to the 150 operators delivering dementia care to 3100 elderly each and every day in New Zealand.

The independent 2010 Aged Residential Care Review also established the rest home care subsidy was 40% underfunded and the hospital rate 17% underfunded. Unfortunately, these underfunding levels have increased over the last two years as inflationary pressures for these services have not been met.

In 2011, about 3100 people were in dementia care, 11,000 in hospital level care and 16,700 in rest home level care.

Follow this link:
NZACA Welcomes $7 million Increase for Dementia

Rates Of Dementia In Underdeveloped Countries Are Double Than Previously Reported

Editor's Choice Main Category: Alzheimer's / Dementia Article Date: 23 May 2012 - 15:00 PDT

Current ratings for: 'Rates Of Dementia In Underdeveloped Countries Are Double Than Previously Reported'

In addition, the team found that just like in developed countries, education offers substantial protection against dementia in less developed nations. The study is published Online First in The Lancet.

Lead study author Martin Prince from King's College London said:

Our findings suggest that early life influences, education and learning to read and write, may be particularly important for reducing the risk of dementia in late life. We need to understand more about cognitive reserve, how to measure it, and how it is stimulated across cultures.

The high incidence of dementia in less developed countries remind us that we are facing a global epidemic, and there needs to be more focus on prevention."

Using conventional western diagnostic approaches, such as the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV criteria, earlier studies have suggested that the incidence of dementia might be significantly lower in low- and middle-income countries vs. high-income nations.

However, the new 10/66 Dementia Diagnosis approach uses methods developed and validated in 25 low and middle-income countries. The new approach has been demonstrated to provide accurate diagnoses even in individuals with little or no education.

In order to the compare the incidence of dementia, and to determine whether education and literacy, among other factors are protective against the development of dementia, the team applied both the standard DSM-IV criteria and the 10/66 approach to around 12,800 individuals aged 65+, across 9 urban and rural sites in Mexico, Cuba, Peru, Venezuela, the Dominican Republic, and China.

The researchers found that the 10/66 dementia incidence is 1.5 - 2.5 times higher than the standard DSM-IV criteria calculated. In addition, 10/66 dementia incidence was consistently comparable to, or high than, dementia incidence reported by earlier studies.

Continue reading here:
Rates Of Dementia In Underdeveloped Countries Are Double Than Previously Reported

Shop staff will be trained to help dementia sufferers

Ministers believe the basic training in dementia awareness is relevant to anyone working in a public environment, such as shops, transport and banks.

Speaking at the event in East London, the Prime Minister urged businesses to join his national fightback against dementia.

Mr Cameron said companies should do more to make people with dementia able to use their services.

He declared that tackling the disease, which is thought to affect 670,000 people in England, was one of his personal priorities.

Dementia is a terrible, heart breaking disease, he said. Tackling it is a personal priority of mine.

Already 20 big organisations like Lloyds Group, Tesco and E.On have signed up to become more dementia-friendly and over the coming months I want to see many more follow suit.

For the sake of millions in our country weve got to keep this spirit of energy and defiance alive.

Were going to keep searching for treatments, keep looking for ways to make life easier for those with this disease and keep taking the fight to dementia.

Mr Cameron urged young volunteers with the National Citizen Service to help sufferers in care homes.

The youngsters aged 16 and 17 are being asked to help dementia patients take part in craft activities and to take them on trips out of care homes.

Continued here:
Shop staff will be trained to help dementia sufferers

Proposal advances for minimum standards in nursing homes, special dementia care units

By Kay Lazar, Globe Staff

A loophole in Massachusetts law that allows nursing homes to advertise specialized Alzheimers and dementia care units, even though their workers may have no training in caring for such residents, is one step closer to being closed.

A proposal that would establish minimum standards for such units was approved by the House of Representatives Wednesday, and is headed for the state Senate.

The bill would require the Massachusetts Department of Public Health, which regulates nursing homes, to establish minimum standards for facilities with dementia care units.

Similar legislation has been proposed for the past seven years without success, supporters said. But this is the first time the measure has made it this far, this early in the year, they said.

This is certainly way overdue, said James Wessler, president and chief executive of the Alzheimers Association of Massachusetts and New Hampshire.

Often nursing home placement is done in time of crisis, and families are then not good shoppers, Wessler said. So the state has an obligation to have a minimal level of guarantees that facilities are providing the level of dementia care that they say they are giving.

Massachusetts is one of a handful of states without such requirements. A 2005 federal report noted that 44 states at that time had requirements governing training, staffing, security, and other areas for facilities that provided specialized dementia care.

The Massachusetts legislation would require all licensed nursing homes to provide dementia-specific training for all direct-care workers, activities directors, and supervisors. Supporters said it was important to mandate dementia training for staff at all licensed facilities because more than half of people in nursing homes suffer from dementia, even if they are not living in specialized dementia care units.

Additionally, the legislation stipulates that there should be activities programs in dementia special care units that provide activities geared to people with dementia.

Go here to see the original:
Proposal advances for minimum standards in nursing homes, special dementia care units

Dementia app spots early signs of condition

British scientists developed an iPad-based memory test that can spot dementia in its earliest stages, when treatment can be most beneficial.

Researchers from Cambridge University helped to develop the CANTABmobile test, which assesses patients' short-term memory with a series of challenges in which they have to remember symbols.

Trials show that the computer program accurately distinguishes normal age-related forgetfulness from dementia and other treatable memory problems.

Dr. John O'Loan, who tested the app at his lab in Warrington, northwestern England, said, "Not everyone with memory problems has dementia. There are a small number of medical conditions -- vitamin deficiencies or an underactive thyroid -- that we check for if patients have problems with their memory."

Doctors currently use pen-and-paper tests to screen for the condition, with patients asked a series of questions including the date and whether they can spell "world" backwards.

However, the tests can fail to pick up dementia, particularly in patients with higher academic qualifications.

The iPad app is far more sensitive, even picking up mild cognitive impairment, which can be a precursor to dementia.

Michael Hurt, Dementia Care Program Manager for NHS Walsall added, "We might find that we get people through the system more quickly and more effectively because the screening tool is more accurate, and that's better for GPs, hospital staff, as well as the people receiving the test."

Click for more from Sky News.

Follow this link:
Dementia app spots early signs of condition

Prayer for Mercy: Henderson family seeks a cure for 6-year-old's unique condition

Leila Navidi

Mercy Doyle, 6, visits with Tina Lindquist, the program director at Brain Balance Achievement Centers in Henderson on Wednesday, May 23, 2012. Doyle has been diagnosed with the rare neurological disorder Opsoclonus MyoclonusSyndrome.

By Conor Shine (contact)

Thursday, May 24, 2012 | 2 a.m.

Six-year-old Mercy Doyle is like a lot of girls her age.

She loves coloring, swimming and The Little Mermaid. She looks up to her big sister and finds her younger brother kind of annoying.

But to doctors in Nevada and around the country, Mercy is a medical mystery, a child with a unique set of symptoms theyve never seen before.

Mercys medical odyssey began seemingly overnight, her parents say, four years ago during a family vacation to the beach in California.

She kept falling in the sand. She couldnt run around. She was shaky. It was weird, said her father, Kevin Doyle, a worship pastor at Green Valley Christian Center.

Her family rushed back home to Henderson, where Mercy was diagnosed with a viral infection that was attacking her brain. After a few months, her condition seemed to be improving. Then her symptoms worsened again.

Continue reading here:
Prayer for Mercy: Henderson family seeks a cure for 6-year-old's unique condition

Prayer for Mercy: Henderson family seeks a cure for 6-year-old’s unique condition

Leila Navidi

Mercy Doyle, 6, visits with Tina Lindquist, the program director at Brain Balance Achievement Centers in Henderson on Wednesday, May 23, 2012. Doyle has been diagnosed with the rare neurological disorder Opsoclonus MyoclonusSyndrome.

By Conor Shine (contact)

Thursday, May 24, 2012 | 2 a.m.

Six-year-old Mercy Doyle is like a lot of girls her age.

She loves coloring, swimming and The Little Mermaid. She looks up to her big sister and finds her younger brother kind of annoying.

But to doctors in Nevada and around the country, Mercy is a medical mystery, a child with a unique set of symptoms theyve never seen before.

Mercys medical odyssey began seemingly overnight, her parents say, four years ago during a family vacation to the beach in California.

She kept falling in the sand. She couldnt run around. She was shaky. It was weird, said her father, Kevin Doyle, a worship pastor at Green Valley Christian Center.

Her family rushed back home to Henderson, where Mercy was diagnosed with a viral infection that was attacking her brain. After a few months, her condition seemed to be improving. Then her symptoms worsened again.

Continue reading here:
Prayer for Mercy: Henderson family seeks a cure for 6-year-old's unique condition

Sam Bridgman: The University of Portland comes together to help support one of its own

One night last November, players on the University of Portland men's and women's basketball teams joined forces to compete in one of the toughest games of their lives.

What the students lost by in points that night, they gained in perspective: They got to see a glimmer of what life is like each day for their classmate and friend Sam Bridgman.

Bridgman, a junior finance major, has a condition called Friedreich's ataxia, a rare, degenerative neuro-muscular disorder that causes progressive loss of coordination and muscle strength.

About 550 people attended the event, which raised more than $7,000 toward research for Friedreich's ataxia and offered Bridgman the opportunity to educate his classmates about his condition.

It also gave Bridgman's classmates on the campus of about 3,810 students the chance to show him what he means to them.

"Although SamJam is a more formal event, it just shows what goes on every day with him -- how we all feel about him and that we just want to help him out," says Sam Westendorf, a member of the school's Student Athlete Advisory Committee who helped organize the event.

Bridgman, a Seattle native, grew up a happy, outgoing kid who loved people and baseball -- and pretty much every other sport. His mother, Amy Koepnick, recalls how her son could make 3-pointers from the age of 7.

But his body first began behaving strangely when Bridgman was playing basketball in middle school.

"When I would rebound the ball I would box out, see the ball come off the rim, and I would tell my body to go get it, but it wouldn't move," he recalls while eating lunch on campus in the company of two close baseball buddies and his girlfriend, Molly Billingham.

Bridgman's symptoms were gradual and easy to dismiss as growing pains. It took years for a diagnosis because the condition is so rare. It wasn't until he was 15 that a pediatric neurologist in Seattle finally put a name to his body's inexplicable rebellion.

See more here:
Sam Bridgman: The University of Portland comes together to help support one of its own

MONROE: Towns went âBlueâ for National Autism Month

MONROE April was recognized across the United States as National Autism Month and served as an opportunity for everyone to educate the public about autism and the issues within the autism community.

Resident Kimberley Toto decided to go bigger this year and promoted more awareness during World Autism Awareness Day April 2, and not only included the schools but made it a community wide event and asked the two local communities to light it up blue.

This marked her third year promoting this campaign through Autism Speaks, where prominent buildings across North America turned their lights blue in honor of World Autism Awareness Day.

The Empire State Building in New York City did the same thing to promote awareness for the condition.

Inspired by this, Ms. Toto used spotlights and blue Christmas lights on her home in April.

Autism spectrum disorder (ASD) and autism are both general terms for a group of complex disorders of brain development. These disorders are characterized, in varying degrees, by difficulties in social interaction, verbal and nonverbal communication and repetitive behaviors, according to the Autism Speaks website, http://www.autismspeaks.org.

When my daughter was diagnosed it was 1 in 150. In the last several years the numbers increased to 1 in 110, Ms. Toto said. Right before the month of April 2012, the Centers for Disease Control came out with new numbers. It is now 1 in 88 kids that are affected with some form of ASD (Autism Spectrum Disorder).

Autism statistics from the U.S. Centers for Disease Control and Prevention (CDC) identify around 1 in 88 American children as on the autism spectruma 10-fold increase in prevalence in 40 years, according to the organization. Careful research shows that this increase is only partly explained by improved diagnosis and awareness.

Studies also show that autism is three to four times more common among boys than girls. An estimated 1 out of 54 boys and 1 in 252 girls are diagnosed with autism in the United States, according to the Autism Speaks website.

By way of comparison, this is more children than are affected by diabetes, AIDS, cancer, cerebral palsy, cystic fibrosis, muscular dystrophy or Down syndrome, combined, according to the organization.

See the original post here:
MONROE: Towns went âBlueâ for National Autism Month

Fevers during pregnancy linked to autism, but medication helps

Women who reported having had a fever during pregnancy were more likely to give birth to a baby who would later be diagnosed with autism spectrum disorder or a development delay, says a major new study. But the babies of women who treated their fevers with medication fared no worse than babies whose mothers recalled having suffered no fevers at all.

The findings, wrote the authors, "suggest that anti-fever medication used to control fever during pregnancy can reduce or eliminate" the apparent link between maternal fever and autism.

The study, by researchers at UC Davis' MIND Institute, was published in the Journal of Autism and Developmental Disorders. It wades into a tempestuous debate over what environmental factors in pregnancy might contribute to autism -- and to an apparent increase in autism over the last several decades. Several studies have yielded conflicting findings over whether a link exists between infections during pregnancy and a baby's risk for autism. Many of those studies, however, have been marred by small population sizes and their reliance on a mother's recall, or medical records, of infection.

The current study, called Childhood Autism Risks from Genetics and Environment (CHARGE), sought to avoid those pitfalls. Researchers enrolled babies and their mothers into the major population study when the infants were between the ages of 2 and 5. Between January 2003 and September 2010, 1,122 babies were enrolled--538 diagnosed with autism spectrum disorder, 163 with developmental delays that were not thought to be autism, and 421 typically developing children. Their mothers were interviewed at length about their pregnancies; whether they were vaccinated against flu; whether and when in their pregnancies they suffered infection, flu, or fevers; and what medication, if any, they took in response.

Researchers found no link between a woman's report of having had influenza--or a flu vaccine shot--during pregnancy, and the baby that would go on to have autism or developmental delay. But asking about fevers--the body's immune response to a wide range of infections, including influenza--yielded a different response.

All told, 191 of the participating mothers reported that they had suffered a fever in the course of pregnancy. Of those, 76 said they treated themselves with medication designed to lower fever--products containing acetaminophen or ibuprofen. But 115 did not take any such medication, or reported they took medication that would not have acted to lower fever.

Compared with babies whose mothers reported no fevers during pregnancy, the babies of mothers who had fevers were about 2 1/2 times more likely to be diagnosed later with a communications disorder on the autism spectrum, and 2 3/4 times more likely to have developmental delays.

Medication to drive down elevated body temperature helped avoid developmental delays by a little: When a pregnant woman took fever medication, her baby's odds of having a developmental delay went down to twice the probability of a mother-baby pair that experienced no fevers.

But medication to drive down fever appeared to markedly drive down the odds that a baby would go on to be diagnosed with autism spectrum disorder. The babies of these women were only about 30% more likely to develop autism.

The results, suggest the authors, parallel findings in pregnant rats and mice--that when an animal's massive inflammatory response to an infection is suppressed, the development of behavioral abnormalities in the resulting offspring is reduced.

Read this article:
Fevers during pregnancy linked to autism, but medication helps

Most Children With Autism Diagnosed at 5 or Older

Data Provide Snapshot of Autism Spectrum Disorder and Special Health Care Needs

By Denise Mann WebMD Health News

Reviewed by Louise Chang, MD

May 24, 2012 -- New research provides a snapshot of what life is like for school-aged children with autism spectrum disorder in the U.S.

The findings, which appear in the NCHS Data Brief, highlight areas where there is room for improvement, including earlier diagnosis of autism spectrum disorder and access to behavioral therapies and other services. The new study looked at children aged 6 to 17 with special health care needs and autism spectrum disorder in 2011.

More than half of school-aged kids were age 5 or older when they were first diagnosed with autism spectrum disorder, the study showed. Less than 20% were diagnosed by age 2. The American Academy of Pediatrics recommends that pediatricians screen children for autism at 18 months of age.

The CDC estimates that 1 in 88 children in the U.S. has an autism spectrum disorder. This is the umbrella term for a group of developmental disorders that can range from mild to severe and that often affect social and communication skills. Treatment is individualized, and often involves behavioral therapies to address developmental delays along with medication.

Of the children in the study, about 9 of 10 received one or more therapies. Most commonly these included speech or language therapy and/or social skills training. More than half of these kids took at least one psychiatric medication, including stimulants, anti-anxiety drugs, or antidepressants.

"Our data indicate that many children with autism -- the majority -- are getting some sort of services such as speech or other individual-based interventions," says researcher Lisa J. Colpe, PhD, MPH, of the National Institute of Mental Health in Bethesda, Md. "That is great news."

Outside experts say there are still many gaps in the diagnosis and treatment of autism spectrum disorder among school-aged kids in the U.S.

See original here:
Most Children With Autism Diagnosed at 5 or Older

Stem cells take root in drug development

Stem cells have assumed near-mythical status in the popular imagination as a possible cure for every disease under the sun. But while public attention has focused on their potential in regenerative medicine, stem cells have quietly gained a foothold in drug development a move that may hail a huge but unheralded shake-up of the biological sciences.

I think there are tremendous parallels to the early days of recombinant DNA in this field, says James Thomson, director of regenerative biology at the Morgridge Institute for Research in Madison, Wisconsin, and one of the founders of Cellular Dynamics International, also in Madison. I dont think people appreciated what a broad-ranging tool recombinant DNA was in the middle '70s." At the same time, he says, they underestimated the difficulty of using it in treatments.

Now stem cells are in a similar situation, he says, and although therapeutic use is likely to come to fruition eventually, people underappreciate how broadly enabling a research tool it is, he says.

Laboratory-grown stem cells hold much promise for regenerative medicine, but are being increasingly used in drug testing.

MASSIMO BREGA, THE LIGHTHOUSE/SCIENCE PHOTO LIBRARY

Drug companies began dipping a tentative toe into the stem-cell waters about two years ago (see 'Testing time for stem cells'). Now, the pharmaceutical industry is increasingly adopting stem cells for testing the toxicity of drugs and identifying potential new therapies, say those in the field.

Cellular Dynamics sells human heart cells called cardiomyocytes, which are derived from induced pluripotent stem (iPS) cells. Thomson says that essentially all the major pharma companies have bought some. The company also produces brain cells and cells that line blood vessels, and is about to release a line of human liver cells.

Yet Cellular Dynamics is just one of the companies in the field. Three years ago, stem-cell biologist Stephen Minger left his job in UK academia to head GE Healthcares push into stem cells (see 'Top scientist's industry move heralds stem-cell shift'). The medical-technology company, headquartered in Chalfont St. Giles, UK, has been selling human heart cells made from embryonic stem (ES) cells for well over a year, and is due to start selling liver cells soon.

Minger and his team at GE Healthcare assessed the heart cells in a blind trial against a set of unnamed drug compounds to see if the cells would reveal which compounds were toxic. When the compounds were unmasked, Minger says, they found that the cells had been affected by the known toxic compounds. But, crucially, in a number of cases, the cells identified a problem that had only been discovered after the drugs had reached the market and after they had been approved by agencies such as the US Food and Drug Administration (FDA).

These are compounds which went all the way through animal testing, then went through phase I, II, III and then were licensed in many cases by the FDA, says Minger.

See the original post:
Stem cells take root in drug development

Man's 'Race to the Clouds' will help fight Parkinson’s disease

WAPELLO, Iowa Riding a motorcycle takes a steady hand. Although Jeff Weikert doesnt have that luxury anymore, that wont stop him from riding.

In 2009, Weikert, 51, of Wapello, was diagnosed with Parkinsons disease, a degenerative disorder of the central nervous system. The disease hasnt stopped him from riding, though.

The career motorcycle and stock car racer signed up to participate in the 90th edition of the Pikes Peak International Hill Climb, also known as the Race to the Clouds, in Colorado Springs, Colo.

To participate, one has to submit a resume of personal racing history. After Weikert submitted his on Dec. 1, 2011, his wife, Angie, 46, said they were invited to participate in the race.

Its fine with me, and hes been racing since Ive known him, Angie said. Its one more race that was on his bucket list.

Angie said the last race that her husband participated in was in 2010 for District 17, an American Motorcycle Association organization that competes in Illinois. She described that race as featuring specialty made cycles through an obstacle course.

Its timed, but slow and about balancing, Angie said. His Parkinsons prevented him from competing again after he was diagnosed.

For the race in Colorado, Weikert will ride a 1974 Honda 250cc motorcycle. The cycle was built and is owned by Paynes Cycle Center in Rock Island. He is only one of two riders from Iowa to compete in the 200-man race.

Heading to Colorado with Jeff and his wife for the race on July 8 are their two sons, Jonathan and Jacob and Jacobs wife, Jessica. Others include members of Paynes Cycle Center and other friends and family to help with their fundraising.

After Jeff was diagnosed, he and his wife sought information about the disease through the Michael J. Fox Foundation for Parkinsons Research. For the race, the Weikerts have teamed up with the foundation to help raise awareness and money.

Original post:
Man's 'Race to the Clouds' will help fight Parkinson’s disease

Man’s ‘Race to the Clouds’ will help fight Parkinson’s disease

WAPELLO, Iowa Riding a motorcycle takes a steady hand. Although Jeff Weikert doesnt have that luxury anymore, that wont stop him from riding.

In 2009, Weikert, 51, of Wapello, was diagnosed with Parkinsons disease, a degenerative disorder of the central nervous system. The disease hasnt stopped him from riding, though.

The career motorcycle and stock car racer signed up to participate in the 90th edition of the Pikes Peak International Hill Climb, also known as the Race to the Clouds, in Colorado Springs, Colo.

To participate, one has to submit a resume of personal racing history. After Weikert submitted his on Dec. 1, 2011, his wife, Angie, 46, said they were invited to participate in the race.

Its fine with me, and hes been racing since Ive known him, Angie said. Its one more race that was on his bucket list.

Angie said the last race that her husband participated in was in 2010 for District 17, an American Motorcycle Association organization that competes in Illinois. She described that race as featuring specialty made cycles through an obstacle course.

Its timed, but slow and about balancing, Angie said. His Parkinsons prevented him from competing again after he was diagnosed.

For the race in Colorado, Weikert will ride a 1974 Honda 250cc motorcycle. The cycle was built and is owned by Paynes Cycle Center in Rock Island. He is only one of two riders from Iowa to compete in the 200-man race.

Heading to Colorado with Jeff and his wife for the race on July 8 are their two sons, Jonathan and Jacob and Jacobs wife, Jessica. Others include members of Paynes Cycle Center and other friends and family to help with their fundraising.

After Jeff was diagnosed, he and his wife sought information about the disease through the Michael J. Fox Foundation for Parkinsons Research. For the race, the Weikerts have teamed up with the foundation to help raise awareness and money.

Original post:
Man's 'Race to the Clouds' will help fight Parkinson’s disease

Kiss Goodbye to Multiple Sclerosis

Kiss Goodbye to Multiple Sclerosis

May 25 June 5 is MS Awareness Week, where we are all encouraged to learn more about the condition and Kiss Goodbye to MS.

Although MS can affects vision, balance and speech, living with MS does not have to mean the loss of independence in the home.

Tunstall Healthcare provides a personal alarm that allows the wearer to activate a call for assistance and puts them in immediate contact with Tunstalls 24 hour response centre, where the necessary assistance can be organised.

Tunstalls personal alarm can also be interfaced with a fall detector to help manage an increased tendency to fall.

Living with MS does not have to mean a loss of independence with help always available at the press of a button.

To find out more about MS and MS Awareness week visit http://www.msqld.org.

About Tunstall Healthcare With over 2.5 million users globally, Tunstall is the market leading provider of telecare and telehealth solutions. Across Australia Tunstalls solutions support older people and those with long term needs to live independently, by effectively managing their health and wellbeing. Tunstall provides technology, expertise and advice to millions of people enabling them to lead independent more fulfilling lives. For more information on how telecare and telehealth can improve quality of life, visit http://www.tunstallhealthcare.com.au.

ENDS

See the article here:
Kiss Goodbye to Multiple Sclerosis

Nature Neuroscience Study Shows Unique Scientific Support for Potential New Myelin Repair Treatment for Multiple …

SARATOGA, Calif.--(BUSINESS WIRE)--

The Myelin Repair Foundation (MRF) today announced the results of a new peer-reviewed research study published in Nature Neuroscience that demonstrates functional improvement in immune response modulation and myelin repair with factors derived from mesenchymal stem cell (MSC) treatment in animal models of multiple sclerosis (MS). Funded by the Myelin Repair Foundation, this research conducted by Case Western Reserve University scientists showed positive results with human mesenchymal stem cells in animal models of MS by not only successfully blocking the autoimmune MS response, but also repairing myelin, demonstrating an innovative potential myelin repair treatment for MS.

Multiple sclerosis is a disease of the immune system that attacks the myelin, causing exposed nerves or lesions which block brain signals, causing loss of motor skills, coordination and cognitive ability. Compared to the controls, this research study showed fewer and smaller lesions found on the nerves in the MSC treatment group. MSCs were found to block the formation of scar tissue by suppressing the autoimmune response, which would otherwise cause permanent damage to the nerves. Furthermore, the research showed that MSC treatment also repaired myelin, enhancing myelin regeneration of the damaged axon and the rewrapping of the myelin around the axon in animal models of MS. One treatment of MSCs provided long-term protection of the recurring disease.

Led by Myelin Repair Foundation Principal Investigator and Vice President for Research & Technology Management at Case Western Reserve Universitys Dr. Robert Miller, this study documents a new promising pathway for treating multiple sclerosis that blocks the autoimmune response and reverses the myelin damage in animal models of MS. The human MSCs used in this study were culled from adult stem cells derived from the bone marrow.

We are thrilled with the publication of this important research study that examines a new pathway to treat multiple sclerosis, one that reverses the damage of the disease, said Dr. Robert Miller. Since we were just beginning to understand how MSCs provide myelin repair for lesions, with the Myelin Repair Foundations support, we continue to deepen our knowledge of exploring the next generation of MS treatments that stimulate healing, rather than symptom suppression of the disease.

We pride ourselves on supporting best-in-class scientists devoted to find new ways to treat multiple sclerosis, advancing highly innovative research projects that otherwise would not have moved forward, said Scott Johnson, president of the Myelin Repair Foundation. The success of Case Western Reserve Universitys study and recognition in this prestigious journal furthers our goal to identify new pathways to treat multiple sclerosis by supporting a multi-disciplinary team of the best researchers in the field.

About the Myelin Repair Foundation

The Myelin Repair Foundation (MRF) (http://www.myelinrepair.org) is a Silicon Valley-based, non-profit research organization focused on accelerating the discovery and development of myelin repair therapeutics for multiple sclerosis. Its Accelerated Research Collaboration (ARC) model is designed to optimize the entire process of medical research, drug development and the delivery of patient treatments.

Read more from the original source:
Nature Neuroscience Study Shows Unique Scientific Support for Potential New Myelin Repair Treatment for Multiple ...

The Post published Golden age for research into dementia in Bristol

A BRISTOL scientist believes the city is entering a golden age for research into dementia.

The city has long been a leading centre for research into Alzheimer's and other forms of the brain disorder both nationally and internationally but a Bristol University professor believes that ongoing projects in the city could lead to treatments being developed to help patients.

Professor Seth Love examining a brain at the brain bank at Frenchay Hospital. Left, Chief executive of Brace Mark Poarch

And professor of neuropathology Seth Love credited a small Bristol charity for funding much of the early research that has led to the larger trials that could see huge strides being made in the treatment of dementia in coming years.

Brace, which is based at Frenchay Hospital, is celebrating its 25th anniver- sary of funding research into Alzheimer's in Bristol, Bath and Cardiff.

As well as celebrating the landmark, the charity which started when people were still doubtful about the impact research could have on dementia can celebrate its involvement with an initial study that could lead to a drug being made available to ease the symptoms and early progression of dementia.

Prof Love said that much of the research that is now being carried out into Alzheimer's in the South West Dementia Group has come out of research conducted in the brain bank on the Frenchay Hospital site.

"For quite a while now we have been one of the leading pre-clinical dementia research groups in the UK with a strong international reputation," he said.

"And to a large extent that is down to Brace who have been funding and providing core support for many years.

"Without Brace we would not exist. As a result of the work which has been done with the support of the South West Dementia Brain Bank and Brace funding, I think we are really entering a golden age in dementia research here in Bristol and are now in a position to take some of the research advances that we have made here with the brain bank with support from Brace and other charities and the research can be translated then into treatments for patients with dementia."

More:
The Post published Golden age for research into dementia in Bristol